Nephrocare Health Services Limited
Nephrocare Health Services Limited (NEPHROPLUS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider
nephroplus.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 260 Cr | 266 Cr | 282 Cr |
| Operating expenses (approx.) | 199 Cr | 212 Cr | 218 Cr |
| EBITDA | 61 Cr | 54 Cr | 64 Cr |
| OPM % | 23.4% | 20.2% | 22.7% |
| Other income | 3 Cr | 12 Cr | 7 Cr |
| Interest | 6 Cr | 3 Cr | 2 Cr |
| Depreciation | 22 Cr | 26 Cr | 25 Cr |
| Profit before tax | 36 Cr | 33 Cr | 41 Cr |
| Tax % | 11.3% | 8.6% | 22.1% |
| Net profit | 32 Cr | 30 Cr | 32 Cr |
| EPS (₹) | ₹3.43 | ₹3.03 | ₹3.19 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 999 Cr | Sign in for TTM |
| Operating expenses (approx.) | 772 Cr | Sign in for TTM |
| EBITDA | 227 Cr | Sign in for TTM |
| OPM % | 22.7% | Sign in for TTM |
| Other income | 25 Cr | Sign in for TTM |
| Interest | 60 Cr | Sign in for TTM |
| Depreciation | 91 Cr | Sign in for TTM |
| Profit before tax | 97 Cr | Sign in for TTM |
| Tax % | 21.2% | Sign in for TTM |
| Net profit | 77 Cr | Sign in for TTM |
| EPS (₹) | ₹8.48 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 20 Cr |
| Reserves | 1,096 Cr |
| Borrowings | 80 Cr |
| Other liabilities | 275 Cr |
| Total liabilities | 1,471 Cr |
| Fixed assets (net) | 396 Cr |
| CWIP | 6 Cr |
| Investments | 178 Cr |
| Inventories | 33 Cr |
| Trade receivables | 317 Cr |
| Cash & bank | 124 Cr |
| Other assets | 418 Cr |
| Total assets | 1,471 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 233 Cr |
| Cash from investing | -410 Cr |
| Cash from financing | 157 Cr |
| Net cash flow | -2 Cr |
| Free cash flow (OCF − Capex) | 113 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 13.2% |
| ROE % | 6.9% |
| Debtor days | 115 |
| Inventory days | 53 |
| Days payable | 230 |
| Cash conversion cycle | -61 |
| Debt / equity | 0.07 |
| Current ratio | 2.80 |
| Net debt / EBITDA | -0.19 |
Compare with peers
Loading peers…